AbbVie wins EU nod for Rinvoq in Crohn's disease
vzphotos/iStock Editorial via Getty Images
- AbbVie (NYSE:ABBV) announced Monday that an expert medical panel in the EU recommended marketing authorization for its oral JAK inhibitor Rinvoq, known as upadacitinib in generic terms, for adults with the gastrointestinal disorder Crohn's disease.
- Specifically, the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has endorsed upadacitinib for adults with moderately to severely active Crohn's disease in whom conventional therapy or biologic agents failed. Patients can also be intolerant to conventional treatments or biologic agents to receive upadacitinib.
- A chronic, systemic condition, Crohn's disease is characterized by inflammation in the gastrointestinal tract leading to diarrhea and abdominal pain.
- If the European Commission (EC) confirms the CHMP's view, Crohn's disease will be the seventh indication where upadacitinib is indicated in the EU, AbbVie (ABBV) said.
- Read: Seeking Alpha contributor The Value Pendulum recently issued a Hold rating on AbbVie (ABBV), noting the prospects for its topline growth and forward P/E multiple.